Results 161 to 170 of about 22,482 (226)

Comparison of Choroidal Morphological Changes Between Aflibercept 8 mg and Faricimab-svoa in Treatment-Naïve Polypoidal Choroidal Vasculopathy and Pachychoroid Neovasculopathy. [PDF]

J Clin Med
Jeong S, Seong SH, Sagong M.
europepmc   +1 more source

Prospective Real-World Outcomes After Switching to Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration with High Treatment Burden. [PDF]

Ophthalmol Ther
Spartalis C, Ullrich M, Winkler S, Leisser C, Ruiss M, Pilwachs C, Findl O.   +6 more
europepmc   +1 more source

Macular Neovascular Membrane as a Late Complication of Acute Posterior Multifocal Placoid Pigment Epitheliopathy (APMPPE) Managed With Intravitreal Aflibercept. [PDF]

Case Rep Ophthalmol Med
Couto AP, Fernandes BF, Vianna RNG.
europepmc   +1 more source

Placental Growth Factor in Diabetic Retinopathy: Disease-Selective Signaling and Mechanistic Rationale for Targeted Therapy. [PDF]

Int J Mol Sci
Kim J, Ju WK, Won JY.
europepmc   +1 more source

Aflibercept biosimilar use and real-world outcomes in various retinal diseases: the AURA Korea study. [PDF]

Sci Rep
Song JR, Jeon J, Baek SC, Sharma A, Sagong M, Lee CS, Woo SJ, International Retina Biosimilar Study Group (Inter BIOS Group).   +7 more
europepmc   +1 more source

Biosimilars of anti-VEGF agents in retinal diseases: a narrative review of regulatory, clinical, and pharmacoeconomic aspects. [PDF]

Int J Retina Vitreous
Zong Y, Fan Q, Huang L.
europepmc   +1 more source

Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US. [PDF]

Ophthalmol Ther
Kuznik A, Coughlan A, Pinsent A, Toro-Diaz H, Sherman S, Patel NA.   +5 more
europepmc   +1 more source

Real World Data About the Treatment of Wet Age-Related Macular Degeneration in Kuopio University Hospital During 2019-2021 Using a PRN Regimen. [PDF]

Clin Ophthalmol
Hiltunen TO, Kaarniranta K, Kivinen N.
europepmc   +1 more source

Functional Real-World Outcomes of Aflibercept 8 mg Versus Faricimab After Loading Phase in Diabetic Macular Edema. [PDF]

Ophthalmol Ther
Menna F, Calabro M, Guillot A, De Luca L, Meduri A, Baldascino A, Lupo S, Vingolo EM.   +7 more
europepmc   +1 more source

Short-term efficacy of aflibercept 8 mg in refractory neovascular age-related macular degeneration: a retrospective case series from Taiwan. [PDF]

BMC Ophthalmol
Chi SC, Hwang DK, Chen SJ, Weng CC, Huang YM, Chou YB, Lin TC.   +6 more
europepmc   +1 more source